Last reviewed · How we verify
Fluarix™ YB
Fluarix YB is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.
Fluarix YB is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains. Used for Seasonal influenza prevention in adults and children.
At a glance
| Generic name | Fluarix™ YB |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus antigens from three or four seasonal strains, which trigger both humoral and cellular immune responses. Upon vaccination, the body produces specific antibodies and T-cell responses that provide protection against infection with matching circulating influenza viruses during the flu season.
Approved indications
- Seasonal influenza prevention in adults and children
Common side effects
- Injection site soreness or erythema
- Myalgia
- Headache
- Fatigue
- Low-grade fever
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Fluarix™ YB CI brief — competitive landscape report
- Fluarix™ YB updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI